Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl L Alden

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Toxicologic Pathology|July 30, 2009
The re-emergence (or the decline) of toxicologic pathologyCarl L Alden
Toxicologic Pathology|June 14, 2011
Re: analysis of pharmaceutical experience with decades of rat carcinogenicity testing. Introduction to article by Sistare et alDaniel Morton, Carl L Alden
Veterinary Pathology|May 12, 2009
Confidence in rodent carcinogenesis bioassaysJerrold M Ward, Carl L Alden
Toxicologic Pathology|October 19, 2012
Improving carcinogenicity assessmentDaniel Morton, Todd Bourcier, Carl L Alden
Toxicologic Pathology|March 14, 2002
The Tg rasH2 mouse in cancer hazard identificationDaniel Morton, Carl L Alden, Arthur J Roth, et al.
Neurotoxicology|December 25, 2007
Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitroVilmos Csizmadia, Arek Raczynski, Eva Csizmadia, et al.
Chemical Research in Toxicology|April 20, 2004
Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profilingJeffrey A Kramer, Sandra W Curtiss, Kyle L Kolaja, et al.
Toxicologic Pathology|April 5, 2005
Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role for metabolic and oxidative stress in nongenotoxic carcinogenicityMollisa M Elrick, Jeffrey A Kramer, Carl L Alden, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Toxicologic Pathology|July 30, 2009
The re-emergence (or the decline) of toxicologic pathologyCarl L Alden
Toxicologic Pathology|June 14, 2011
Re: analysis of pharmaceutical experience with decades of rat carcinogenicity testing. Introduction to article by Sistare et alDaniel Morton, Carl L Alden
Veterinary Pathology|May 12, 2009
Confidence in rodent carcinogenesis bioassaysJerrold M Ward, Carl L Alden
Toxicologic Pathology|October 19, 2012
Improving carcinogenicity assessmentDaniel Morton, Todd Bourcier, Carl L Alden
Toxicologic Pathology|March 14, 2002
The Tg rasH2 mouse in cancer hazard identificationDaniel Morton, Carl L Alden, Arthur J Roth, et al.
Neurotoxicology|December 25, 2007
Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitroVilmos Csizmadia, Arek Raczynski, Eva Csizmadia, et al.
Chemical Research in Toxicology|April 20, 2004
Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profilingJeffrey A Kramer, Sandra W Curtiss, Kyle L Kolaja, et al.
Toxicologic Pathology|April 5, 2005
Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role for metabolic and oxidative stress in nongenotoxic carcinogenicityMollisa M Elrick, Jeffrey A Kramer, Carl L Alden, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
Pageof 1